http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 14 Oct 2026 16:05:23 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Board+Changes/Lisata+Therapeutics+adds+Jeffrey+Farrow+to+its+board+of+directors/27187130.html <p>Lisata Therapeutics, Inc. (Nasdaq: LSTA) announced the appointment of Jeffrey Farrow to its board of directors, effective October 13, 2026, expanding the board from seven to eight members.</p> <p>Farrow fills a newly created Class III director seat, appointed upon the recommendation of the Nominating and Corporate Governance Committee. He will also serve on the Audit Committee. The board has determined that Farrow qualifies as independent under Nasdaq listing rules.</p> <p>Farrow currently serves as Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS). He also sits on the boards of Clover Biopharmaceuticals, Ltd. (HKEX) and Achieve Life Sciences, Inc. http://www.streetinsider.com/Board+Changes/Lisata+Therapeutics+adds+Jeffrey+Farrow+to+its+board+of+directors/27187130.html Wed, 14 Oct 2026 16:05:23 -0400 ACHV LSTA TARS http://www.streetinsider.com/Board+Changes/Lisata+Therapeutics+adds+Jeffrey+Farrow+to+its+board+of+directors/27187130.html <p>Lisata Therapeutics, Inc. (Nasdaq: LSTA) announced the appointment of Jeffrey Farrow to its board of directors, effective October 13, 2026, expanding the board from seven to eight members.</p> <p>Farrow fills a newly created Class III director seat, appointed upon the recommendation of the Nominating and Corporate Governance Committee. He will also serve on the Audit Committee. The board has determined that Farrow qualifies as independent under Nasdaq listing rules.</p> <p>Farrow currently serves as Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS). He also sits on the boards of Clover Biopharmaceuticals, Ltd. (HKEX) and Achieve Life Sciences, Inc. http://www.streetinsider.com/Board+Changes/Lisata+Therapeutics+adds+Jeffrey+Farrow+to+its+board+of+directors/27187130.html Wed, 14 Oct 2026 16:05:23 -0400 ACHV LSTA TARS http://www.streetinsider.com/Board+Changes/Lisata+Therapeutics+adds+Jeffrey+Farrow+to+its+board+of+directors/27187130.html <p>Lisata Therapeutics, Inc. (Nasdaq: LSTA) announced the appointment of Jeffrey Farrow to its board of directors, effective October 13, 2026, expanding the board from seven to eight members.</p> <p>Farrow fills a newly created Class III director seat, appointed upon the recommendation of the Nominating and Corporate Governance Committee. He will also serve on the Audit Committee. The board has determined that Farrow qualifies as independent under Nasdaq listing rules.</p> <p>Farrow currently serves as Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS). He also sits on the boards of Clover Biopharmaceuticals, Ltd. (HKEX) and Achieve Life Sciences, Inc. http://www.streetinsider.com/Board+Changes/Lisata+Therapeutics+adds+Jeffrey+Farrow+to+its+board+of+directors/27187130.html Wed, 14 Oct 2026 16:05:23 -0400 ACHV LSTA TARS http://www.streetinsider.com/Press+Releases/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html <p><strong>Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee</strong></p><p>LIBERTY CORNER, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”) today announced the appointment of Jeffrey Farrow to its Board of Directors, effective October 13, 2026.</p> <p>Mr. Farrow fills a newly created seat, expanding the Board from seven to eight members. He was appointed as a Class III director upon the recommendation of the Nominating and Corporate Governance Committee and will also serve on the Audit Committee. The Board http://www.streetinsider.com/Press+Releases/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html Wed, 14 Oct 2026 16:05:00 -0400 ACHV LSTA TARS http://www.streetinsider.com/Globe+Newswire/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html <p><strong>Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee</strong></p><p>LIBERTY CORNER, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”) today announced the appointment of Jeffrey Farrow to its Board of Directors, effective October 13, 2026.</p> <p>Mr. Farrow fills a newly created seat, expanding the Board from seven to eight members. He was appointed as a Class III director upon the recommendation of the Nominating and Corporate Governance Committee and will also serve on the Audit Committee. The Board http://www.streetinsider.com/Globe+Newswire/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html Wed, 14 Oct 2026 16:05:00 -0400 ACHV LSTA TARS http://www.streetinsider.com/Press+Releases/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html <p><strong>Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee</strong></p><p>LIBERTY CORNER, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”) today announced the appointment of Jeffrey Farrow to its Board of Directors, effective October 13, 2026.</p> <p>Mr. Farrow fills a newly created seat, expanding the Board from seven to eight members. He was appointed as a Class III director upon the recommendation of the Nominating and Corporate Governance Committee and will also serve on the Audit Committee. The Board http://www.streetinsider.com/Press+Releases/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html Wed, 14 Oct 2026 16:05:00 -0400 ACHV LSTA TARS http://www.streetinsider.com/Globe+Newswire/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html <p><strong>Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee</strong></p><p>LIBERTY CORNER, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”) today announced the appointment of Jeffrey Farrow to its Board of Directors, effective October 13, 2026.</p> <p>Mr. Farrow fills a newly created seat, expanding the Board from seven to eight members. He was appointed as a Class III director upon the recommendation of the Nominating and Corporate Governance Committee and will also serve on the Audit Committee. The Board http://www.streetinsider.com/Globe+Newswire/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html Wed, 14 Oct 2026 16:05:00 -0400 ACHV LSTA TARS http://www.streetinsider.com/Press+Releases/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html <p><strong>Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee</strong></p><p>LIBERTY CORNER, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”) today announced the appointment of Jeffrey Farrow to its Board of Directors, effective October 13, 2026.</p> <p>Mr. Farrow fills a newly created seat, expanding the Board from seven to eight members. He was appointed as a Class III director upon the recommendation of the Nominating and Corporate Governance Committee and will also serve on the Audit Committee. The Board http://www.streetinsider.com/Press+Releases/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html Wed, 14 Oct 2026 16:05:00 -0400 ACHV LSTA TARS http://www.streetinsider.com/Globe+Newswire/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html <p><strong>Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee</strong></p><p>LIBERTY CORNER, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”) today announced the appointment of Jeffrey Farrow to its Board of Directors, effective October 13, 2026.</p> <p>Mr. Farrow fills a newly created seat, expanding the Board from seven to eight members. He was appointed as a Class III director upon the recommendation of the Nominating and Corporate Governance Committee and will also serve on the Audit Committee. The Board http://www.streetinsider.com/Globe+Newswire/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html Wed, 14 Oct 2026 16:05:00 -0400 ACHV LSTA TARS http://www.streetinsider.com/Management+Changes/Achieve+Life+Sciences+names+Kaitlyn+Tuson+as+SVP+of+Marketing/27158507.html <p>Achieve Life Sciences, Inc. (Nasdaq: ACHV) has appointed Kaitlyn Tuson as Senior Vice President of Marketing and Communications, according to a company statement.</p> <p>Tuson, who brings 15 years of healthcare marketing experience, will lead the company's marketing, brand strategy, and corporate communications. Her background includes go-to-market leadership across more than 40 therapeutic areas globally, with six pharmaceutical product launches, three of which the company describes as blockbuster therapies.</p> <p>Chief Executive Officer Andrew D. Goldberg, MD, said Tuson's experience in brand building, product launch strategy, and patient engagement will be relevant as the company advances toward a planned NDA resubmission for cytisinicline, its http://www.streetinsider.com/Management+Changes/Achieve+Life+Sciences+names+Kaitlyn+Tuson+as+SVP+of+Marketing/27158507.html Wed, 07 Oct 2026 08:30:30 -0400 ACHV http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Appoints+Kaitlyn+Tuson+as+Senior+Vice+President%2C+Marketing+and+Communications/27158493.html <p>SEATTLE and VANCOUVER, British Columbia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve and the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced the appointment of Kaitlyn (Kait) Tuson as Senior Vice President, Marketing and Communications. Tuson joins Achieve’s executive team and will lead its marketing, brand strategy, and corporate communications as the Company prepares for the potential commercialization of cytisinicline.</p> <p>Tuson has spent 15 years building, launching, and scaling brands across the healthcare industry, with go-to-market http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Appoints+Kaitlyn+Tuson+as+Senior+Vice+President%2C+Marketing+and+Communications/27158493.html Wed, 07 Oct 2026 08:30:00 -0400 ACHV http://www.streetinsider.com/Globe+Newswire/Achieve+Life+Sciences+Appoints+Kaitlyn+Tuson+as+Senior+Vice+President%2C+Marketing+and+Communications/27158493.html <p>SEATTLE and VANCOUVER, British Columbia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve and the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced the appointment of Kaitlyn (Kait) Tuson as Senior Vice President, Marketing and Communications. Tuson joins Achieve’s executive team and will lead its marketing, brand strategy, and corporate communications as the Company prepares for the potential commercialization of cytisinicline.</p> <p>Tuson has spent 15 years building, launching, and scaling brands across the healthcare industry, with go-to-market http://www.streetinsider.com/Globe+Newswire/Achieve+Life+Sciences+Appoints+Kaitlyn+Tuson+as+Senior+Vice+President%2C+Marketing+and+Communications/27158493.html Wed, 07 Oct 2026 08:30:00 -0400 ACHV http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ACHIEVE+LIFE+SCIENCES%2C++++For%3A+Oct+05++Filed+by%3A+Halladay+Benjamin/27155681.html si-local-file:///var/storage/secattach/20261006/27155681.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ACHIEVE+LIFE+SCIENCES%2C++++For%3A+Oct+05++Filed+by%3A+Halladay+Benjamin/27155681.html Tue, 06 Oct 2026 16:15:00 -0400 ACHV http://www.streetinsider.com/SEC+Filings/Form++3++++++++++ACHIEVE+LIFE+SCIENCES%2C++++For%3A+Oct+05++Filed+by%3A+Halladay+Benjamin/27155633.html si-local-file:///var/storage/secattach/20261006/27155633.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++ACHIEVE+LIFE+SCIENCES%2C++++For%3A+Oct+05++Filed+by%3A+Halladay+Benjamin/27155633.html Tue, 06 Oct 2026 16:14:00 -0400 ACHV http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Announces+Granting+of+New+Hire+Inducement+Awards/27155355.html <p align="left">SEATTLE and VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that its board of directors approved stock option grants to purchase an aggregate of 46,500 shares of its common stock and restricted stock unit (“RSU”) awards covering an aggregate of 44,500 shares of its common stock for four new employees. Achieve also announced that the board of directors approved an inducement award grant to http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Announces+Granting+of+New+Hire+Inducement+Awards/27155355.html Tue, 06 Oct 2026 16:02:00 -0400 ACHV http://www.streetinsider.com/Globe+Newswire/Achieve+Life+Sciences+Announces+Granting+of+New+Hire+Inducement+Awards/27155355.html <p align="left">SEATTLE and VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that its board of directors approved stock option grants to purchase an aggregate of 46,500 shares of its common stock and restricted stock unit (“RSU”) awards covering an aggregate of 44,500 shares of its common stock for four new employees. Achieve also announced that the board of directors approved an inducement award grant to http://www.streetinsider.com/Globe+Newswire/Achieve+Life+Sciences+Announces+Granting+of+New+Hire+Inducement+Awards/27155355.html Tue, 06 Oct 2026 16:02:00 -0400 ACHV http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ACHIEVE+LIFE+SCIENCES%2C++++For%3A+Oct+01/27136857.html si-local-file:///var/storage/secattach/20261001/27136857.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ACHIEVE+LIFE+SCIENCES%2C++++For%3A+Oct+01/27136857.html Thu, 01 Oct 2026 16:50:00 -0400 ACHV http://www.streetinsider.com/Management+Changes/Achieve+Life+Sciences+names+Benjamin+Halladay+as+CFO/27132169.html <p>Achieve Life Sciences, Inc. (NASDAQ: ACHV) announced the appointment of Benjamin Halladay as Chief Financial Officer, effective October 5, 2026, according to a company press release. He succeeds Mark Oki, who served as CFO through the company's Phase 3 program and NDA submission.</p> <p>Halladay joins from Esperion Therapeutics, a commercial-stage pharmaceutical company with more than $400 million in annual revenue, where he served as CFO from November 2022 until July 2026. During that period, Esperion deleveraged its balance sheet, acquired Corstasis Therapeutics and its product Enbumyst, and was sold to ARCHIMED for up to $1.1 billion. The upfront cash consideration represented http://www.streetinsider.com/Management+Changes/Achieve+Life+Sciences+names+Benjamin+Halladay+as+CFO/27132169.html Thu, 01 Oct 2026 08:31:50 -0400 ACHV http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Appoints+Benjamin+Halladay+as+Chief+Financial+Officer/27132116.html <p>SEATTLE and VANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced the appointment of Benjamin Halladay, CPA, as Chief Financial Officer, effective October 5, 2026. He will be responsible for the Company’s financial strategy, accounting, investor relations, information technology, and other key administrative functions. </p> <p>Mr. Halladay joins Achieve from Esperion Therapeutics, a commercial-stage pharmaceutical company with more than $400 million in annual revenue, where he http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Appoints+Benjamin+Halladay+as+Chief+Financial+Officer/27132116.html Thu, 01 Oct 2026 08:30:00 -0400 ACHV http://www.streetinsider.com/Globe+Newswire/Achieve+Life+Sciences+Appoints+Benjamin+Halladay+as+Chief+Financial+Officer/27132116.html <p>SEATTLE and VANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced the appointment of Benjamin Halladay, CPA, as Chief Financial Officer, effective October 5, 2026. He will be responsible for the Company’s financial strategy, accounting, investor relations, information technology, and other key administrative functions. </p> <p>Mr. Halladay joins Achieve from Esperion Therapeutics, a commercial-stage pharmaceutical company with more than $400 million in annual revenue, where he http://www.streetinsider.com/Globe+Newswire/Achieve+Life+Sciences+Appoints+Benjamin+Halladay+as+Chief+Financial+Officer/27132116.html Thu, 01 Oct 2026 08:30:00 -0400 ACHV http://www.streetinsider.com/New+Coverage/Stifel+Starts+Achieve+Life+Sciences+%28ACHV%29+at+Buy/27122622.html (Updated - September 29, 2026 4:14 PM EDT) <p>Stifel analyst James Condulis initiates coverage on Achieve Life Sciences (NASDAQ: ACHV) with a Buy rating, PT $18.00.</p><p>The analyst comments "We're initiating coverage of ACHV with a Buy and $18 TP. Our thesis boils down to a view that, after an important transformation of the company (new manufacturer/leadership/strategy/capital), cytisinicline's smoking cessation approval is de-risked and the necessary tools are now in-place to realize what we think is a potential blockbuster opportunity. Commercial is the focus where there are credible debates-- and admittedly, aspects of this story are tricky to diligence. That said--discussed within--we http://www.streetinsider.com/New+Coverage/Stifel+Starts+Achieve+Life+Sciences+%28ACHV%29+at+Buy/27122622.html Tue, 29 Sep 2026 16:14:09 -0400 ACHV http://www.streetinsider.com/Analyst+Comments/Stifel+Starts+Achieve+Life+Sciences+%28ACHV%29+at+Buy/27122622.html (Updated - September 29, 2026 4:14 PM EDT) <p>Stifel analyst James Condulis initiates coverage on Achieve Life Sciences (NASDAQ: ACHV) with a Buy rating, PT $18.00.</p><p>The analyst comments "We're initiating coverage of ACHV with a Buy and $18 TP. Our thesis boils down to a view that, after an important transformation of the company (new manufacturer/leadership/strategy/capital), cytisinicline's smoking cessation approval is de-risked and the necessary tools are now in-place to realize what we think is a potential blockbuster opportunity. Commercial is the focus where there are credible debates-- and admittedly, aspects of this story are tricky to diligence. That said--discussed within--we http://www.streetinsider.com/Analyst+Comments/Stifel+Starts+Achieve+Life+Sciences+%28ACHV%29+at+Buy/27122622.html Tue, 29 Sep 2026 16:14:09 -0400 ACHV http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+to+Present+52-Week+Cytisinicline+Efficacy+Data+for+Smoking+and+E-Cigarette+Cessation+at+CHEST+2026/27110602.html <p>SEATTLE and VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that new data evaluating the efficacy of 52 weeks of cytisinicline treatment for cigarette smoking and e-cigarette cessation will be presented at CHEST 2026, held October 18-21 in Phoenix, Arizona.</p> <p><strong>CHEST 2026 Presentation Details</strong></p> <ul type="disc"><li style="margin-bottom:8pt;">Presentation Title: Efficacy of 52-Week Cytisinicline Treatment for Cigarette Smoking and E-Cigarette Cessation: The Open-Label ORCA-OL Trial</li><li style="margin-bottom:8pt;">Session: Top Late-Breaking Abstracts: http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+to+Present+52-Week+Cytisinicline+Efficacy+Data+for+Smoking+and+E-Cigarette+Cessation+at+CHEST+2026/27110602.html Mon, 28 Sep 2026 08:30:00 -0400 ACHV http://www.streetinsider.com/Globe+Newswire/Achieve+Life+Sciences+to+Present+52-Week+Cytisinicline+Efficacy+Data+for+Smoking+and+E-Cigarette+Cessation+at+CHEST+2026/27110602.html <p>SEATTLE and VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that new data evaluating the efficacy of 52 weeks of cytisinicline treatment for cigarette smoking and e-cigarette cessation will be presented at CHEST 2026, held October 18-21 in Phoenix, Arizona.</p> <p><strong>CHEST 2026 Presentation Details</strong></p> <ul type="disc"><li style="margin-bottom:8pt;">Presentation Title: Efficacy of 52-Week Cytisinicline Treatment for Cigarette Smoking and E-Cigarette Cessation: The Open-Label ORCA-OL Trial</li><li style="margin-bottom:8pt;">Session: Top Late-Breaking Abstracts: http://www.streetinsider.com/Globe+Newswire/Achieve+Life+Sciences+to+Present+52-Week+Cytisinicline+Efficacy+Data+for+Smoking+and+E-Cigarette+Cessation+at+CHEST+2026/27110602.html Mon, 28 Sep 2026 08:30:00 -0400 ACHV http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ACHIEVE+LIFE+SCIENCES%2C++++For%3A+Aug+19++Filed+by%3A+Stewart+Richard+Alistair/26961776.html si-local-file:///var/storage/secattach/20260821/26961776.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ACHIEVE+LIFE+SCIENCES%2C++++For%3A+Aug+19++Filed+by%3A+Stewart+Richard+Alistair/26961776.html Fri, 21 Aug 2026 16:30:00 -0400 ACHV O.00644671